Therapy News and Research

RSS

Provenge cellular immunotherapy for men with advanced prostate cancer receives FDA approval

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

30 Apr 2010

Researchers identify key protein that regulates innate immune system

A team of researchers led by Baylor College of Medicine has identified a protein called NLRC5, a member of the NOD-like protein family, that is involved in inhibition of protein complexes key to critical pathways of innate immunity called NF-κB and type I interferon signaling. A report on their work appears in the current issue of the journal Cell.

30 Apr 2010

Canadian researchers identify new therapeutic target for lung cancer

Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.

30 Apr 2010

Depomed attributes 56% increase in first-quarter revenue to $5.8M increase in Glumetza product sales

Depomed, Inc. today reported financial results for the first quarter ended March 31, 2010.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

FDA approves Provenge prostate cancer vaccine

Cancer may now be fought with a vaccine. The FDA has finally approved an immune boosting vaccine which is said to extend survival of patients at an advanced stage of prostate cancer by four months. This is twice as long as what could be expected with regular chemotherapy. There is also an increase of three years survival after detection in initial stage by 38% thanks to the vaccine.

30 Apr 2010

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Celgene Corporation announced non-GAAP net income of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010. Non-GAAP net income for the first quarter of 2009 was $205.1 million or non-GAAP diluted earnings per share of $0.44. Based on U.S. GAAP, Celgene reported net income of $234.4 million, or diluted earnings per share of $0.50 for the quarter ended March 31, 2010. GAAP net income for the first quarter of 2009 was $162.9 million, or diluted earnings per share of $0.35.

29 Apr 2010

The OCD Project challenges six severe OCD sufferers to face fears in a bold move to better their lives

Obsessive-Compulsive Disorder is a disorder of the brain where people experience obsessive thoughts, images, ideas or impulses – and they can't get past them. The day-to-day existence for severe OCD sufferers is dire. Untreated, they lead lives of self-punishment, fear and isolation that can result in job loss, broken families, bankruptcy and in some cases death.

29 Apr 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.

29 Apr 2010

Non-Surgical Orthopaedics: Shoulder and upper extremity injuries are very common

Shoulder and upper extremity injuries are very common according to Non-Surgical Orthopaedics, P.C. Many of them result from years of cumulative injuries punctuated by a trauma such as a motor vehicle accident, falls, or sports injuries. These injuries cost consumers, their employers and insurance companies billions of dollars a year in treatment and productivity losses.

29 Apr 2010

Power3 Medical Products to present four abstracts at International Congress of Alzheimer's Disease

Power3 Medical Products, Inc. announced that four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimer's Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the NuroPro AD biomarkers and blood test for Alzheimer's disease.

29 Apr 2010

Oncos Therapeutics completes $5.5M investment from HealthCap

Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a - 4 million ($ 5.5 million) investment from HealthCap. With committed capital exceeding - 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

29 Apr 2010

Genetic test to predict newborns requiring hospital readmission shortly after birth

The results of two separate research studies taking place at Children's Mercy Hospitals and Clinics will help physicians use genetic testing to prevent complications, and ease the worry of new parents by predicting in advance which newborns may require readmission to the hospital shortly after birth. The studies also will help physicians identify which of their young patients are likely to respond well - or not - to steroid therapy for asthma.

29 Apr 2010

Removing unruptured AVM decreases risk of hemorrhaging, provides better outcomes to patients

Individuals diagnosed with a brain arteriovenous malformation, an abnormal tangle of arteries and veins, are at an increased risk of vessel rupture and bleeding that can cause stroke and permanent brain damage.

29 Apr 2010

Americans' confidence in their ability to access and pay for healthcare declines

Americans' confidence in their ability to access and pay for healthcare continued to decline last month, according to a new consumer sentiment index from Thomson Reuters.

29 Apr 2010

Cardiac Science responds to FDA communications on AED recall

Cardiac Science Corporation, responded to FDA communications released yesterday related to the AED recall first announced in November, 2009. The Agency communication specifies additional affected models and offers further guidance to users of AEDs affected by potential component defects in some of the Company's AEDs.

29 Apr 2010

Oncology unit of Jewish General Hospital focuses on Smart for Life cookies

Smart for Life cookies will be the focus of a study in the oncology unit of the Jewish General Hospital, acknowledged as a world leader in many fields of investigation and a key teaching site for McGill University.

29 Apr 2010

CINJ trial targets new combination therapy for advanced solid tumors

Building off recent laboratory discoveries relating to how cancer cells become resistant to therapies that attempt to starve cancer, scientists at The Cancer Institute of New Jersey (CINJ) are now applying that knowledge to a process in which cancer cells eat themselves to downsize and resist therapy. The ultimate goal of this effort is to improve upon current anticancer treatments.

29 Apr 2010

New theory on muscle and bone diseases

Traditionally, doctors and clinicians thought diseases that affect muscles or bones affected those areas specifically. For example, bone diseases only affect bones, or muscle diseases only concerned muscles. But recent evidence supports the notion that bones and muscles are more interconnected than previously thought.

29 Apr 2010

Physicists and oncologists to develop novel ultra sensitive platform for early cancer detection

The SPEDOC project will create the precursor to future devices for individualized diagnosis and monitoring of cancer therapy, which will allow the illness to be treated in earlier stages and at lower doses, reducing or preventing current secondary effects.

29 Apr 2010

Therapy News and Research

Provenge cellular immunotherapy for men with advanced prostate cancer receives FDA approval

Researchers identify key protein that regulates innate immune system

Canadian researchers identify new therapeutic target for lung cancer

Depomed attributes 56% increase in first-quarter revenue to $5.8M increase in Glumetza product sales

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

FDA approves Provenge prostate cancer vaccine

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

The OCD Project challenges six severe OCD sufferers to face fears in a bold move to better their lives

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

Non-Surgical Orthopaedics: Shoulder and upper extremity injuries are very common

Power3 Medical Products to present four abstracts at International Congress of Alzheimer's Disease

Oncos Therapeutics completes $5.5M investment from HealthCap

Genetic test to predict newborns requiring hospital readmission shortly after birth

Removing unruptured AVM decreases risk of hemorrhaging, provides better outcomes to patients

Americans' confidence in their ability to access and pay for healthcare declines

Cardiac Science responds to FDA communications on AED recall

Oncology unit of Jewish General Hospital focuses on Smart for Life cookies

CINJ trial targets new combination therapy for advanced solid tumors

New theory on muscle and bone diseases

Physicists and oncologists to develop novel ultra sensitive platform for early cancer detection

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News